Imanivec

Imatinib, the active ingredient in Imanivec, is a tyrosine kinase inhibitor presented as an oral dosage form for oral use. It treats chronic myeloid leukemia and gastrointestinal stromal tumor in adult patients.

GNH USA supplies Imanivec as a licensed, GDP-compliant international pharmaceutical supplier serving hospitals, oncology centres, pharmacies and clinics worldwide.

Imatinib is a targeted therapy that inhibits specific tyrosine kinases involved in certain cancers.

- Chronic myeloid leukemia (CML): improves survival and achieves disease control. - Gastrointestinal stromal tumor (GIST): reduces tumor growth and lowers recurrence risk. - Other BCR‑ABL positive leukemias: provides disease control in eligible patients.

Imatinib may cause a range of adverse reactions that vary in frequency and severity.

Common Side Effects: - Nausea: mild to moderate upset stomach. - Edema: swelling, especially around the ankles. - Muscle cramps: intermittent tightness or pain. - Fatigue: general tiredness. - Diarrhea: loose stools. - Rash: skin irritation or redness.

Serious or Rare Side Effects: - Neutropenia: marked reduction in white blood cells. - Hepatotoxicity: elevated liver enzymes or liver injury. - Cardiac failure: signs of reduced heart function. - Severe fluid retention: rapid weight gain or pleural effusion. - Hemorrhage: abnormal bleeding. - Interstitial lung disease: breathing difficulties and cough.

Before initiating therapy, clinicians should evaluate baseline health status and monitor patients regularly.

- Blood count monitoring: perform complete blood counts to detect cytopenias. - Liver function assessment: check hepatic enzymes periodically. - Cardiac evaluation: assess heart function in patients with pre‑existing cardiac disease. - Infection vigilance: avoid use in patients with active severe infections. - Pregnancy and lactation: use only if potential benefit justifies potential risk. - Store at room temperature: keep in the original container, protect from moisture and direct sunlight.

Imatinib interacts with several medicines that can alter its plasma concentration or increase toxicity.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin): may raise imatinib levels. - CYP3A4 inducers (e.g., rifampicin, carbamazepine): may reduce efficacy. - Warfarin: increased anticoagulant effect, risk of bleeding.

Moderate Interactions (Monitor Closely): - Other tyrosine‑kinase inhibitors: additive toxicity risk. - Diuretics: may exacerbate fluid retention. - QT‑prolonging agents: monitor cardiac rhythm. - Vaccines (live attenuated): assess timing relative to therapy.